跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 14,753 条关于
“MET exon 14 skipping alteration”
全部
14,753
临床试验
7,508
药物
913
机构
240
资讯
6,092
去年
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC with MET Exon 14 Skipping Alterations
3个月前
FDA Approves FoundationOne CDx as Companion Diagnostic for Tepotinib in MET Exon 14-Positive NSCLC
去年
Savolitinib Plus TAGRISSO® Shows 56% Response Rate in MET-High Lung Cancer, HUTCHMED Reports
去年
Tepotinib Shows High Frequency of Adverse Events but Manageable Safety Profile in MET Exon 14-Altered NSCLC
4年前
HUTCHMED Announces Savolitinib sNDA Accepted in China for NSCLC Treatment
9个月前
HUTCHMED Secures Continued NRDL Coverage for Three Cancer Drugs and Gains Commercial Insurance Access for Tazemetostat in China
去年
Capmatinib Demonstrates Sustained Efficacy in MET Exon 14-Mutated NSCLC
去年
HUTCHMED Reports 65% Growth in Oncology Products Revenue, Achieves Profitability in 2024
去年
Tempus Study Shows Concurrent RNA and DNA Sequencing Improves Actionable Variant Detection in NSCLC
去年
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Tepotinib in NSCLC
第 1 页，共 610 页
上一页
下一页
